Immunotherapy: T cells get a ride
Nature Reviews Cancer 17, 333 (2017).
doi:10.1038/nrc.2017.39
Author: M. Teresa Villanueva
Strategies that inhibit the immune checkpoint blockade (ICB) and reactivate T cells using monoclonal antibodies against programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1) have been used to successfully treat immunogenic tumours, and recent efforts have focused on combining this approach with
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: M. Teresa Villanueva Tags: Research Highlight Source Type: research